Examining Health Policy, Payer, Provider, and Patient Perspectives in Indolent Non-Hodgkin’s Lymphoma
During this highly interactive session, panelists and experts representing policy makers, payers, providers, and patients will debate key challenges in iNHL management in light of recent health policy changes, new value-based models of care delivery, and unprecedented advances in targeted therapies. Collaborative strategies for delivering quality patient-centered care and achieving the potential of iNHL-related advances to optimize patient outcomes will be addressed.
This program is intended for hematologists, oncologists, midlevel practitioners, nurses, pharmacists, and other healthcare professionals who manage patients with iNHL.
Following this activity, participants should be able to:
- Develop collaborative strategies to overcome barriers to high-quality interprofessional care of patients with indolent non-Hodgkin’s lymphomas (iNHL)
- Evaluate the current standard of care and emerging treatment options for the management of patients with iNHL, including follicular lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma
- Integrate evidence-based and patient-centered treatment approaches as outlined in clinical practice guidelines into quality- and value-driven models of oncology care for patients with iNHL
Leo I. Gordon, MD, FACP
John & Abby Friend Professor of Oncology Research
Director, Lymphoma Program
Co-Director, Hematologic Malignancies Program
Medical Director, John and Lillian Matthews Center for Cellular Therapy
Northwestern University Feinberg School of Medicine
Robert H. Lurie Comprehensive Cancer Center
Julie M. Vose, MD, MBA
Neumann M. and Mildred E. Harris Professorial Chair
Chief of the Oncology/Hematology Division
University of Nebraska Medical Center
Ritwick Panicker, MD, MMM
Senior Medical Director
New Century Health
Barbara Borrell, RDN, PhD
Blood Cancer Survivor
Member & Volunteer
Leukemia & Lymphoma Society
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below have disclosed the following relevant financial relationships:
Barbara Borrell, RDN, PhD: None
Leo I. Gordon, MD: None
Ritwick Panicker, MD, MMM: None
Julie M Vose, MD, MBA: Grants/Research support from Acerta, Bristol-Myers Squibb, Celgene, Incyte, Janssen Biotech, Kite, Novartis, Seattle Genetics, Spectrum
The activity planning staff listed below has no relevant financial relationships to disclose:
NCCN: Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser
PRIME: Keith Whitener
The clinical information team listed below, who have reviewed content, has the following relevant financial relationships to disclose:
Courtney Smith, PhD: Johnson & Johnson: Equity Interest/Stock Options; Opko Health, Inc: Equity Interest/Stock Options
Tamar Sapir, PhD: PRIME: Salary/Contractual
Cherilyn Heggen-Peay, PhD: PRIME: Salary/Contractual
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NCCN designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.25 contact hours.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.25 hours of Category I credit for completing this activity.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.0125 CEUs) of continuing education credit. UAN: 0836-9999-17-026-L01-P
- 1.25 ACPE contact hours
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC contact hours
- 1.25 Participation